NASDAQ:CODXa molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the growing use of the Company's Vector Smart(TM) NAM-W test by mosquito abatement districts to identify the presence of West Nile virus (WNV).
AVERAGE ANALYSTS PRICE TARGET $2 AVERAGE ANALYSTS RECOMMENDATION BUY P/E RATIO SHORT INTEREST 8.7%
COMPANY PROFILE Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.